LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 47

Search options

  1. Book: Myloid-derived suppressor cells

    Jiménez-Cortegana, Carlos

    (International review of cell and molecular biology ; volume 375)

    2023  

    Author's details edited by Carlos Jiménez-Cortegana, Lorenzo Galluzzi
    Series title International review of cell and molecular biology ; volume 375
    Collection
    Language English
    Size xix, 220 Seiten, Illustrationen
    Edition First edition
    Publisher Elsevier Academic Press
    Publishing place Cambridge, MA
    Publishing country United States
    Document type Book
    HBZ-ID HT021875385
    ISBN 978-0-443-19127-5 ; 0-443-19127-1
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Uc I Zs 317 -375- not available for loan Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Myeloid-derived suppressor cells: Emerging players in cancer and beyond.

    Jiménez-Cortegana, Carlos / Galluzzi, Lorenzo

    International review of cell and molecular biology

    2023  Volume 375, Page(s) xiii–xix

    MeSH term(s) Humans ; Myeloid-Derived Suppressor Cells ; Neoplasms
    Language English
    Publishing date 2023-01-11
    Publishing country Netherlands
    Document type Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2427220-6
    ISSN 1937-6448 ; 0074-7696
    ISSN 1937-6448 ; 0074-7696
    DOI 10.1016/S1937-6448(23)00048-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uc I Zs.317: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The obesity paradox.

    Sánchez-Jiménez, Flora / Jiménez-Cortegana, Carlos

    Medicina clinica

    2023  Volume 161, Issue 8, Page(s) 342–343

    MeSH term(s) Humans ; Obesity Paradox ; Obesity/epidemiology ; Risk Factors ; Body Mass Index
    Language Spanish
    Publishing date 2023-10-19
    Publishing country Spain
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 411607-0
    ISSN 1578-8989 ; 0025-7753
    ISSN (online) 1578-8989
    ISSN 0025-7753
    DOI 10.1016/j.medcli.2023.09.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.279: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Editorial: The regulatory immune system as a target to improve adjuvants and novel vaccines.

    Jiménez-Cortegana, Carlos / Poveda, Cristina / Cabrera, Gabriel

    Frontiers in cellular and infection microbiology

    2023  Volume 13, Page(s) 1223689

    MeSH term(s) Vaccines ; Immune System ; Adjuvants, Immunologic/pharmacology
    Chemical Substances Vaccines ; Adjuvants, Immunologic
    Language English
    Publishing date 2023-06-05
    Publishing country Switzerland
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2023.1223689
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: MDSCs sneak CSCs out of (immuno)surveillance.

    Jiménez-Cortegana, Carlos / Galassi, Claudia / Galluzzi, Lorenzo

    Trends in immunology

    2021  Volume 43, Issue 1, Page(s) 1–3

    Abstract: Cancer stem cells (CSCs) are known for their superior tumor-initiating and tumor-repopulating potential, partly reflecting their pronounced ability to evade immune recognition. Liu and colleagues recently identified a new aldehyde dehydrogenase (ALDH)- ... ...

    Abstract Cancer stem cells (CSCs) are known for their superior tumor-initiating and tumor-repopulating potential, partly reflecting their pronounced ability to evade immune recognition. Liu and colleagues recently identified a new aldehyde dehydrogenase (ALDH)-dependent mechanism whereby triple-negative breast CSCs evade immunosurveillance upon recruitment of myeloid-derived suppressor cells.
    MeSH term(s) Aldehyde Dehydrogenase ; Humans ; Myeloid-Derived Suppressor Cells ; Neoplasms ; Neoplastic Stem Cells
    Chemical Substances Aldehyde Dehydrogenase (EC 1.2.1.3)
    Language English
    Publishing date 2021-12-02
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2036831-8
    ISSN 1471-4981 ; 1471-4906
    ISSN (online) 1471-4981
    ISSN 1471-4906
    DOI 10.1016/j.it.2021.11.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1601: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 2: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors.

    Klapp, Vanessa / Bloy, Norma / Jiménez-Cortegana, Carlos / Buqué, Aitziber / Petroni, Giulia

    Methods in cell biology

    2023  Volume 181, Page(s) 197–212

    Abstract: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (i.e., palbociclib, abemaciclib, and ribociclib) are well known for their capacity to mediate cytostatic effects by promoting cell cycle arrest in the ... ...

    Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (i.e., palbociclib, abemaciclib, and ribociclib) are well known for their capacity to mediate cytostatic effects by promoting cell cycle arrest in the G
    MeSH term(s) Humans ; Female ; Cytostatic Agents/pharmacology ; Flow Cytometry ; Protein Kinase Inhibitors/pharmacology ; Cyclin-Dependent Kinase 6/metabolism ; Cyclin-Dependent Kinase 6/pharmacology ; Cell Cycle Checkpoints ; Cyclin-Dependent Kinase 4/metabolism ; Cyclin-Dependent Kinase 4/pharmacology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cell Cycle
    Chemical Substances Cytostatic Agents ; Protein Kinase Inhibitors ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; CDK4 protein, human (EC 2.7.11.22)
    Language English
    Publishing date 2023-08-22
    Publishing country United States
    Document type Journal Article
    ISSN 0091-679X
    ISSN 0091-679X
    DOI 10.1016/bs.mcb.2023.02.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Myeloid-Derived Suppressor Cells and Radiotherapy.

    Jiménez-Cortegana, Carlos / Galassi, Claudia / Klapp, Vanessa / Gabrilovich, Dmitry I / Galluzzi, Lorenzo

    Cancer immunology research

    2022  Volume 10, Issue 5, Page(s) 545–557

    Abstract: Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically activated, mostly immature, myeloid cells that exert robust immunosuppressive functions. MDSCs expand during oncogenesis and have been linked to accelerated disease ... ...

    Abstract Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically activated, mostly immature, myeloid cells that exert robust immunosuppressive functions. MDSCs expand during oncogenesis and have been linked to accelerated disease progression and resistance to treatment in both preclinical tumor models and patients with cancer. Thus, MDSCs stand out as promising targets for the development of novel immunotherapeutic regimens with superior efficacy. Here, we summarize accumulating preclinical and clinical evidence indicating that MDSCs also hamper the efficacy of radiotherapy (RT), as we critically discuss the potential of MDSC-targeting strategies as tools to achieve superior immunotherapeutic tumor control by RT in the clinic.
    MeSH term(s) Humans ; Myeloid-Derived Suppressor Cells/pathology ; Neoplasms/pathology ; Tumor Microenvironment
    Language English
    Publishing date 2022-04-15
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, Non-U.S. Gov't
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-21-1105
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7022: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: NK cells and solid tumors: therapeutic potential and persisting obstacles.

    Tong, Le / Jiménez-Cortegana, Carlos / Tay, Apple H M / Wickström, Stina / Galluzzi, Lorenzo / Lundqvist, Andreas

    Molecular cancer

    2022  Volume 21, Issue 1, Page(s) 206

    Abstract: Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging responses in patients with leukemia, the ... ...

    Abstract Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging responses in patients with leukemia, the therapeutic effects of NK cell infusion in patients with solid tumors are limited. Preclinical and clinical data suggest that the efficacy of NK cell infusion against solid malignancies is hampered by several factors including inadequate tumor infiltration and persistence/activation in the tumor microenvironment (TME). A number of metabolic features of the TME including hypoxia as well as elevated levels of adenosine, reactive oxygen species, and prostaglandins negatively affect NK cell activity. Moreover, cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells actively suppress NK cell-dependent anticancer immunity. Here, we review the metabolic and cellular barriers that inhibit NK cells in solid neoplasms as we discuss potential strategies to circumvent such obstacles towards superior therapeutic activity.
    MeSH term(s) Humans ; Killer Cells, Natural ; Tumor Microenvironment ; Neoplasms/metabolism ; Myeloid-Derived Suppressor Cells/metabolism
    Language English
    Publishing date 2022-11-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2091373-4
    ISSN 1476-4598 ; 1476-4598
    ISSN (online) 1476-4598
    ISSN 1476-4598
    DOI 10.1186/s12943-022-01672-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Myeloid-derived suppressor cells and vaccination against pathogens.

    Prochetto, Estefanía / Borgna, Eliana / Jiménez-Cortegana, Carlos / Sánchez-Margalet, Víctor / Cabrera, Gabriel

    Frontiers in cellular and infection microbiology

    2022  Volume 12, Page(s) 1003781

    Abstract: It is widely accepted that the immune system includes molecular and cellular components that play a role in regulating and suppressing the effector immune response in almost any process in which the immune system is involved. Myeloid-derived suppressor ... ...

    Abstract It is widely accepted that the immune system includes molecular and cellular components that play a role in regulating and suppressing the effector immune response in almost any process in which the immune system is involved. Myeloid-derived suppressor cells (MDSCs) are described as a heterogeneous population of myeloid origin, immature state, with a strong capacity to suppress T cells and other immune populations. Although the initial characterization of these cells was strongly associated with pathological conditions such as cancer and then with chronic and acute infections, extensive evidence supports that MDSCs are also involved in physiological/non-pathological settings, including pregnancy, neonatal period, aging, and vaccination. Vaccination is one of the greatest public health achievements and has reduced mortality and morbidity caused by many pathogens. The primary goal of prophylactic vaccination is to induce protection against a potential pathogen by mimicking, at least in a part, the events that take place during its natural interaction with the host. This strategy allows the immune system to prepare humoral and cellular effector components to cope with the real infection. This approach has been successful in developing vaccines against many pathogens. However, when the infectious agents can evade and subvert the host immune system, inducing cells with regulatory/suppressive capacity, the development of vaccines may not be straightforward. Notably, there is a long list of complex pathogens that can expand MDSCs, for which a vaccine is still not available. Moreover, vaccination against numerous bacteria, viruses, parasites, and fungi has also been shown to cause MDSC expansion. Increases are not due to a particular adjuvant or immunization route; indeed, numerous adjuvants and immunization routes have been reported to cause an accumulation of this immunosuppressive population. Most of the reports describe that, according to their suppressive nature, MDSCs may limit vaccine efficacy. Taking into account the accumulated evidence supporting the involvement of MDSCs in vaccination, this review aims to compile the studies that highlight the role of MDSCs during the assessment of vaccines against pathogens.
    MeSH term(s) Immunity ; Immunization ; Myeloid-Derived Suppressor Cells ; T-Lymphocytes ; Vaccination
    Language English
    Publishing date 2022-09-29
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2022.1003781
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.

    García-Domínguez, Daniel J / López-Enríquez, Soledad / Alba, Gonzalo / Garnacho, Carmen / Jiménez-Cortegana, Carlos / Flores-Campos, Rocío / de la Cruz-Merino, Luis / Hajji, Nabil / Sánchez-Margalet, Víctor / Hontecillas-Prieto, Lourdes

    International journal of molecular sciences

    2024  Volume 25, Issue 2

    Abstract: Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until today, continues to be a prevalent and lethal disease. Chemotherapy, radiotherapy, and surgery are the conventional treatments, which ...

    Abstract Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until today, continues to be a prevalent and lethal disease. Chemotherapy, radiotherapy, and surgery are the conventional treatments, which have increased the survival for cancer patients. However, the complexity of this disease together with the persistent problems due to tumor progression and recurrence, drug resistance, or side effects of therapy make it necessary to explore new strategies that address the challenges to obtain a positive response. One important point is that tumor cells can interact with the microenvironment, promoting proliferation, dissemination, and immune evasion. Therefore, immunotherapy has emerged as a novel therapy based on the modulation of the immune system for combating cancer, as reflected in the promising results both in preclinical studies and clinical trials obtained. In order to enhance the immune response, the combination of immunotherapy with nanoparticles has been conducted, improving the access of immune cells to the tumor, antigen presentation, as well as the induction of persistent immune responses. Therefore, nanomedicine holds an enormous potential to enhance the efficacy of cancer immunotherapy. Here, we review the most recent advances in specific molecular and cellular immunotherapy and in nano-immunotherapy against cancer in the light of the latest published preclinical studies and clinical trials.
    MeSH term(s) Humans ; Immunotherapy ; Neoplasms/therapy ; Antigen Presentation ; Immune Evasion ; Nanomedicine ; Tumor Microenvironment
    Language English
    Publishing date 2024-01-18
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25021195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top